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Background:Antibiotic treatment of chronicQ fever is cumbersome and of long duration.To
monitor treatment, there is a need for alternative biomarkers. Coxiella burnetii -speciﬁc
interferon (IFN)-γ and interleukin (IL)-2 production reﬂect the type of effector and memory
T-cell response. In chronic Q fever, C. burnetii -speciﬁc IFN-γ production is higher and IL-
2 production is lower than in individuals with past Q fever. Here we explore whether C.
burnetii -speciﬁc IFN-γ and IL-2 production correlate to treatment response.
Methods:We studied the longitudinal C. burnetii -speciﬁc IFN-γ/IL-2 ratio in ﬁfteen proven
chronic Q fever patients. All patients were followed for at least 18 months during antibiotic
treatment. Treatment was considered successful when clinical recovery was observed, a
positive PCR for C. burnetii DNA in blood became persistently negative, anti-phase I IgG
showed a fourfold decrease or more, and imaging techniques showed disappearance of
infectious foci.
Results: Overall, the IFN-γ/IL-2 ratio declined when patients experienced a successful
treatment outcome.When treatment failed, IFN-γ/IL-2 ratios did not signiﬁcantly decrease.
The median (±IQR) slope of the longitudinal IFN-γ/IL-2 ratio with successful treatment
was −2.10 (−7.02 to −0.06), and −0.15 (−1.13 to 0.25) with unsuccessful treatment
(P = 0.19). Q fever endocarditis patients had higher IFN-γ/IL-2 ratios than patients with
endovascular infections.
Conclusion:Wepropose that the IFN-γ/IL-2 ratio can be used as an additional biomarker for
monitoring chronic Q fever treatment, with declining ratios being indicative of successful
treatment.
Keywords: Q fever, Coxiella burnetii, cell-mediated immunity, interferon-gamma, interleukin-2, biomarker, serology,
treatment
INTRODUCTION
Q fever is a zoonosis, caused by the Gram-negative, intracellu-
lar bacterium Coxiella burnetii (Raoult et al., 2005; Parker et al.,
2006). Following primary infection, 1–5% of patients develop
chronic infection, which can become clinically overt months to
years later (Maurin and Raoult, 1999). Endocarditis and infection
of a vascular aneurysm or prosthesis are the most common mani-
festations of chronic Q fever (Botelho-Nevers et al., 2007; Million
et al., 2010). Pre-existent cardiac valvular abnormalities, aortic
aneurysms, vascular grafts, and immune-compromised state are
risk factors (Raoult et al., 2000; Fenollar et al., 2001; Landais et al.,
2007).
Clinical symptoms of chronic Q fever are often non-speciﬁc,
and the diagnosis relies on identifying pre-existing risk-factors, the
results of anti-C. burnetii serology andPCR forC. burnetii DNAon
blood or tissue, and results of imaging techniques (Wegdam-Blans
et al., 2012a; Anderson et al., 2013). Untreated chronic infection
leads to severe morbidity, with a mortality up to 60% (Million
et al., 2010). Long-term antibiotics, preferably doxycycline com-
bined with hydroxychloroquine (Raoult et al., 1999; Kersh, 2013),
are required to eliminate C. burnetii. Antibiotics should be admin-
istered for at least 18 months or, in case of a valvular/vascular
prosthesis, for at least 24 months (Million et al., 2010). Surgi-
cal intervention to replace an infected vascular aneurysm/graft
or cardiac valve is often necessary, either in the acute situation
of a symptomatic aortic aneurysm or heart failure, or when a
patient does not improve on antibiotics (Botelho-Nevers et al.,
2007; Kampschreur et al., 2012; Wegdam-Blans et al., 2012b).
The discontinuation of antimicrobial therapy strongly depends
on the results of follow-up imaging. In case of vascular infec-
tion focus, 18F-ﬂuorodeoxyglucose Positron Emission Tomogra-
phy/Computed Tomography (FDG-PET/CT) is preferred, which
has high sensitivity and speciﬁcity for low-grade vascular infec-
tions (Merhej et al., 2012; Barten et al., 2013). In cases of Q fever
endocarditis, vegetations are difﬁcult to detect on echocardiogra-
phy, and a negative echocardiogram does not rule out endocarditis
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(Maurin and Raoult, 1999). Therefore, serology is an important
tool during the antibiotic treatment of chronic Q fever. Chronic
infection is characterized by high titres of anti-phase I IgG anti-
bodies. It is assumed that antibiotic treatment should be continued
until these titres have declined at least fourfold, or until titres are
below 1:800 in immunoﬂuorescence assay [IFA, or below 1:1024
in a commercial available IFA (Focus Diagnostics)]; (Million et al.,
2010). In daily practice, the slow serological decline requires longer
treatment, and titres often remain above 1:800 (or above 1:1024
respectively) for a prolonged time.
These limitations show the need for additional biomarkers to
monitor treatment of chronic Q fever. In this respect, laboratory
tests measuring cell-mediated immune responses may be of value.
Interferon-gamma (IFN-γ) plays a pivotal role in the immune
response against the intracellular C. burnetii (Dellacasagrande
et al., 1999; Andoh et al., 2007). Analogous to IFN-γ release assays
(IGRAs) that are widely used in Mycobacterium tuberculosis infec-
tion (Pai et al., 2004), we previously used whole-blood assays to
show that the C. burnetii-speciﬁc IFN-γ production is signiﬁ-
cantly increased in people that have been exposed to C. burnetii
(Schoffelen et al., 2013). The interpretation of IFN-γ production
in chronic Q fever is complex, since IFN-γ production is a marker
of both immunity and infection. We demonstrated, by measur-
ing a broad panel of cytokines, that ex-vivo C. burnetii-speciﬁc
IFN-γ production is higher and interleukin (IL)-2 production is
lower in chronic Q fever patients than in patients with past Q
fever (Schoffelen et al., 2014), and concluded that a high IFN-
γ/IL-2 ratio has a high speciﬁcity to discriminate between these
two groups.
The present study follows the hypothesis that the IFN-γ/IL-2
ratio will decline during effective treatment of chronic Q fever.
To test this, we followed 15 chronic Q fever patients for at least
18 months during antibiotic treatment and performed whole-
blood stimulation assays with measurement of IFN-γ and IL-2 on
a regularly basis. This study is the ﬁrst evaluationof a cell-mediated
immunity biomarker for treatment of chronic Q fever.
MATERIALS AND METHODS
PATIENTS AND FOLLOW-UP
Fifteen chronic Q fever patients, recruited from participating hos-
pitals, were followed in this study for at least 18 months. The
study was approved by the Medical Ethical Committee Arnhem-
Nijmegen and written informed consent was obtained from all
subjects. At the time of diagnosis, all patients had a positive PCR in
blood, serumand/or tissue, and anti-phase I IgG titres≥ 1:1024 (in
the absence of acute Q fever). Four patients were diagnosed with
endocarditis according to the modiﬁed Duke criteria (n = 4), and
eleven had vascular infection. All fulﬁlled the criteria of ‘proven
chronic Q fever’ of the Dutch consensus group on chronic Q fever
(Wegdam-Blans et al., 2012a). Patients were included at differ-
ent time points after start of treatment. The start of antibiotic
treatment was designated t = 0. The three patients that were
included at the start of treatment or within 2 months after start of
treatment are described in more detail. Treatment was considered
successful when clinical recovery was observed, a positive PCR
for C. burnetii DNA on blood became persistently negative, anti-
phase I IgG showed a fourfold decrease or more (related to the
maximum titre), and imaging techniques showed disappearance
of any (vascular or valvular) infectious foci.
WHOLE BLOOD INCUBATION
Venous blood drawn into 5 mL endotoxin-free lithium-heparin
tubes (Vacutainer, BD Biosciences) was processed within 12 h.
Blood was aliquoted in separate tubes and incubated at 37◦C for
24 h with heat-inactivated C. burnetii Nine Mile (NM) RSA493
phase I (Seshadri et al., 2003), mitogen (positive control) or
without (negative control).
C. burnetii NM was used in an end-concentration of 107
bacteria/mL. Bacteria were cultured in a BSL-3 facility at the Cen-
tral Veterinary Institute (Lelystad, the Netherlands) as previously
described (Schoffelen et al., 2013) and kindly provided by Dr. H.
J. Roest. The same batch was used for all assays. The mitogen
phytohemagglutinin (PHA, Sigma-Aldrich, St. Louis, MO, USA;
10 μg/mL) was used as a positive control. After incubation, blood
cultures were centrifuged at 4656 g for 10 min and supernatants
were stored at −20◦C until assayed.
CYTOKINE MEASUREMENTS
Interferon-γ concentration in supernatants was measured using
a commercial enzyme-linked immunosorbent assay (ELISA;
Pelikine compact, Sanquin, Amsterdam, the Netherlands) as pre-
viously described (Schoffelen et al., 2014). The background IFN-γ
response of the negative control aliquot was subtracted from the
stimulated aliquots for each individual sample. In all negative
control aliquots, the highest IFN-γ concentration was 46 pg/mL,
which was considered acceptable. In addition, all samples showed
a net IFN-γ production >24 pg/mL in either the positive control
aliquot or in the C. burnetii-stimulated aliquot. Thus, all samples
were considered valid. IL-2 concentrations in supernatant of theC.
burnetii-stimulated aliquots were measured using luminex mag-
netic beads assay (Merck Millipore, Billerica, MA, USA) according
to the manufacturer’s instructions.
ANALYSIS
Graphpad Prism (Graphpad software Inc., version 5) was used to
make the graphs and to analyze the data. Non-linear regression
to a straight line with least square ﬁt was performed to obtain the
best-ﬁt slope of the IFN-γ/IL-2 ratio of each patient over time.
Median ± interquartile range (IQR) slope was compared between
groups.
RESULTS
CASE 1: A PATIENT WITH C. burnetii -INFECTED VASCULAR
PROSTHESIS WITH SUCCESSFUL TREATMENT
A 30-years-old man with a medical history of traumatic rup-
ture of the thoracic aorta, for which he had undergone vascular
surgery receiving an endoprosthesis, suffered from new symp-
toms of malaise, night sweats, weight loss, and chills. Because
of the preceding Q fever epidemic, serology for C. burnetii was
performed, revealing chronic infection with very high IgG titers
against phase I and II (both 1:65536). PCRon serum forC. burnetii
DNA was positive. He was not aware of a preceding acute Q fever
episode. FDG-PET/CT showedno signs of infection at the thoracic
aortic prosthesis, nor elsewhere. Transesophageal echocardiogram
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FIGURE 1 | Detailed overview of immunological parameters in (A)
patient 1 (B) patient 2, and (C) patient 3 from start of antibiotic
treatment to end of study follow-up.The IFN-γ and IL-2 concentrations
(dotted lines) and the IFN-γ/IL-2 ratio (black diamant) are shown on the left
y -axis, the anti-phase I IgG antibody-titer (black triangle) is shown on the right
y -axis. The course of antibiotic treatment is depicted above each graph.
www.frontiersin.org February 2015 | Volume 6 | Article 93 | 3
Schoffelen et al. IFN-γ/IL-2 biomarker for chronic Q-fever
Table 1 | Clinical features of the chronic Q fever patients.
Nr Sex Age
(yrs)a
Focus of infection IgG anti-phase
I titrea,b
IgG anti-phase
II titrea,b
PCR serum/
plasmaa
PCR tissue Duration of antibiotic
treatment (months)c
1 Male 30 Vascular graft 65536 65536 Pos n.a. 0
2 Male 66 Aortic valve 131072 131072 Pos Pos 1
3 Male 64 Aortic aneurysm 8192 8192 Neg Pos 2
4 Male 46 Vascular graft 65536 131072 Pos n.a. 7
5 Female 64 Aortic aneurysm 8192 8192 Pos n.a. 18
6 Male 72 Vascular graft 16384 8192 Neg Pos 9
7 Male 74 Aortic aneurysm 65536 32768 Neg Pos 4
8 Female 54 Vascular graft 4096 4096 Neg Pos 24
9 Male 79 Prosthetic aortic valve 4096 4096 Pos n.a. 20
10 Male 58 Mitral valve 4096 8192 Pos Pos 6
11 Male 67 Vascular graft 4096 4096 Neg Pos 20
12 Female 65 Prosthetic aortic biovalve 8192 16384 Pos n.a. 8
13 Male 71 Vascular graft 2048 4096 Pos Pos 35
14 Male 59 Vascular graft 16384 8192 Pos Pos 29
15 Male 74 Vascular/Spondylodiscitis 8192 8192 Neg Pos 4
n.a., not available; aat the moment of diagnosis of chronic Q fever; bas measured with immunoﬂuorescence assay (IFA, Focus Diagnostics); cat the moment of ﬁrst
blood sample for this study.
(TEE) showed mild aortic valve insufﬁciency without vegetations.
Although infection of the vascular prosthesis could not be detected
with FDG-PET/CT, it was considered the most likely focus of
infection. The patient started antimicrobial therapy with doxy-
cycline and hydroxychloroquine after which he made a quick
clinical recovery. PCR in serum became permanently negative
5 months after start of therapy. Although anti-phase I IgG titers
had decreased from 1:131072 to 1:8192 in 24 months, titers did not
decrease further and moxiﬂoxacin was added to the therapy. This
regimen was continued for another 14 months, after which it was
decided to stop treatment and continue follow-up 3-monthly. The
follow-up –6 months so far– was uneventful. This patient, having
a good response on the antimicrobial therapy, showed peaking of
the IFN-γ/IL-2 ratio during the ﬁrst 9months. Thereafter, the ratio
declined and was stable at lower values during the last phase of the
treatment, analog to the anti-phase I antibody titers (Figure 1A).
CASE 2: A PATIENT WITH C. burnetii ENDOCARDITIS WITH
SUCCESSFUL TREATMENT
A 66-years-old man had a history of aortic valve stenosis with
valvular replacement (homograft) 11 years before. He presented
with symptoms of cardiac failure, for which a TEE was performed,
which showed vegetations on the valvular prosthesis. Screening
for C. burnetii revealed chronic Q fever infection with anti-phase I
and II IgG 1:131072 and a positive C. burnetii PCR in blood. Ther-
apy with doxycycline and hydroxychloroquine was started and the
patient underwent valvular replacement. PCR on valve tissue was
positive for C. burnetii DNA. After 2 months therapy, PCR on
blood was negative and remained so in the follow-up. The patient
recovered well. Although he suffered from side effects (mainly
photo-sensitivity), the antimicrobial therapy could be continued
for 27 months, after which 3-monthly follow-up continued. By
that time, the anti-phase I IgG had declined to 1:2048. After
stop of antimicrobial therapy, the follow-up has been uneventful
(13 months so far).
The IFN-γ/IL-2 ratio showed an initial increase, but from
5 months after start of treatment onward, the IFN-γ/IL-2 ratio
declined to very low values (Figure 1B).
CASE 3: A PATIENT WITH C. burnetii -INFECTED VASCULAR
PROSTHESIS WITH FAILURE OF TREATMENT
In the aftermath of the Q fever epidemic, a 64-years-old man
presented with an acute aneurysm of the abdominal aorta. In
the preceding weeks, he had back pain, fatigue, malaise, and
weight loss. He underwent surgery with placement of a vas-
cular prosthesis, and PCR on aorta tissue was positive for C.
burnetii. Serology revealed elevated titers of anti-phase I and
phase II IgG both 1:8192. PCR for C. burnetii DNA in blood
was negative. He could not recall a preceding episode of fever
or pneumonia. Doxycycline and hydroxychloroquine treatment
was started. A transthoracic echocardiogram (TTE) showed thick-
ening of the aortic valve. The patient refused to undergo TEE.
He recovered well after the operation. However, anti-C. burnetii
IgG titers did not decrease in the subsequent 2 years. PCR for
C. burnetii DNA on blood, performed 3-monthly, remained neg-
ative. Moxiﬂoxacin was added to the therapy after 23 months.
FDG-PET/CT showed increased uptake at the vascular pros-
thesis, indicating a persistent infection. This patient showed
an unsuccessful treatment of a chronic Q fever vascular infec-
tion. The IFN-γ/IL-2 ratio was relatively low from the start
of therapy in this patient. The ratio showed an increase after
the operation after which it remained mildly elevated, with no
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FIGURE 2 | Interferon-γ/IL-2 ratio in C. burnetii -stimulated whole blood
of chronic Q fever patients during the study follow-up period, separately
shown for (A) patients with successful and (B) patients with
unsuccessful treatment. t = 0 is start of antibiotic treatment. Treatment was
considered successful when 18 months of antibiotic treatment (or 24 months
when a prosthesis remained in situ) was completed, and clinically recovery
was observed, and a positive PCR for C. burnetii DNA on blood became
persistently negative, and anti-phase I IgG showed a fourfold decrease or
more (related to the maximum titer), and imaging techniques showed
disappearance of any (vascular or valvular) infection focus. Circles indicate a
positive PCR on blood/serum, squares indicate positive PCR on tissue.
Vertical lines indicate stop of antimicrobial treatment.
tendency to decline (Figure 1C). This was the result of neither
decrease in IFN-γ production nor increase in IL-2 production
over time.
AN OVERVIEW OF THE IFN-γ/IL-2 RATIO IN FOLLOW-UP OF 15 CHRONIC
Q FEVER PATIENTS
We studied the longitudinal IFN-γ/IL-2 ratio in ﬁfteen chronic
Q fever patients (Table 1). All were followed for at least
18 months during antibiotic treatment. In some cases, this
included a period after completion of the treatment. For the
purpose of this study, the data of all patients were analyzed
according to start of antimicrobial therapy (t = 0), which
was up to 35 months before inclusion. We divided the group
in patients with successful treatment (n = 8) and those with
unsuccessful treatment (n = 7; Figure 2). The latter group
did not fulﬁll the success-criteria because of persistent PCR
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FIGURE 3 | Non-linear regression to straight curves of the longitudinal
IFN-γ/IL-2 ratios of chronic Q fever patients. Patients with successful
treatment are shown in green, patients with unsuccessful treatment are
shown in red. The median (±IQR) slope of the patients with successful
treatment was −2.10 (−7.02 to −0.06), compared to −0.15 (−1.13 to 0.25)
in patients with unsuccessful treatment (P = 0.19).
positivity for C. burnetii in blood (patient 9), less than a four-
fold decrease in anti-phase I IgG titer (patient 3, 8, 11, 14),
and/or persistent uptake on FDG-PET/CT (patient 3, 6, 7,
8, 14). As can be seen in Figure 2, the patients with suc-
cessful treatment had higher maximum IFN-γ/IL-2 ratios than
those with unsuccessful treatment. Moreover, the IFN-γ/IL-2
ratio of the patients with successful treatment showed a more
pronounced decrease, each with an individual pattern, com-
pared to the patients with unsuccessful treatment. We performed
non-linear regression of the longitudinal IFN-γ/IL-2 ratios of
each patient to a best-ﬁt straight line (Figure 3). The median
(±IQR) slope of the patients with successful treatment was
−2.10 (−7.02 to −0.06), compared to −0.15 (−1.13 to 0.25)
in patients with unsuccessful treatment (P = 0.19). Because the
two main clinical manifestations of chronic Q fever may dif-
fer immunologically, the patients with endocarditis were also
depicted separately from the patients with vascular (prosthe-
sis) infection (Figure 4). Q fever endocarditis patients had
overall higher IFN-γ/IL-2 ratios than the vascular Q fever
patients.
DISCUSSION
In the present study, we evaluated the usefulness of longitudinal
measurements of cell-mediated immune responses against C. bur-
netii for treatment monitoring of chronic Q fever. We measured
the C. burnetii-speciﬁc IFN-γ and IL-2 production in a whole-
blood stimulation assay during a period of at least 18 months
follow-up of proven chronic Q fever patients. We observed a
trend in which the IFN-γ/IL-2 ratio declined when patients expe-
rienced a successful outcome of treatment. Patients in whom
treatment failed, had overall lower IFN-γ/IL-2 ratios, which did
not signiﬁcantly decrease.
The IFN-γ/IL-2 ratio reﬂects the type of effector and mem-
ory CD4+ T-cell response (Sallusto et al., 1999). Memory T
lymphocytes can broadly be deﬁned as two distinct populations
of effector memory T-cells and central memory T-cells. IFN-γ is
predominately produced by effector T-cells and effector memory
T-cells, while IL-2 is predominately produced by central mem-
ory T-cells. It is postulated that high IFN-γ/IL-2 ratio indicates
predominance of effector T-cells and effector memory T-cells,
resulting from ongoing immunological stimulation by a persistent
infection.
The relevance of measuring IFN-γ/IL-2 production proﬁles,
as diagnostic correlate of memory T-cell responses, has been
studied outside the ﬁeld of Q fever, speciﬁcally in a number of
viral infections (Younes et al., 2003; Semmo et al., 2005), and
in Mycobacterium tuberculosis infection (Sargentini et al., 2009;
Biselli et al., 2010; Casey et al., 2010; Sester et al., 2011; Essone
et al., 2014). These studies, as summarized by Lalvani and Milling-
ton (2008), show that in acute and chronic infections with a high
antigen concentration, e.g., in chronic progressive HCV infection
(Semmo et al., 2005) or untreated tuberculosis (Millington et al.,
2007), CD4+ T-cells predominately secrete IFN-γ. In infections
with persistently low antigen concentrations, e.g., latent asymp-
tomatic cytomegalovirus infection, CD4+ T-cells secreting IFN-γ
only, IFN-γ/IL-2, or IL-2 only are detected (Harari et al., 2005).
In cleared infections, IL-2 secreting CD4+ T-cells predominate
(Harari et al., 2004, 2005; Correa et al., 2007; Millington et al.,
2007). Our ﬁnding that the IFN-γ/IL-2 ratio declines during
successful treatment of chronic Q fever, assuming a decrease in
antigen load, is in accordance with these studies.
The group of patients that was included in our study was
inevitably heterogeneous with regard to morbidity, infection sta-
tus, treatment course and treatment response. Likewise, the
inter-individual variation in IFN-γ and IL-2 responses was large.
We considered it therefore not feasible to combine individual
results for a grouped analysis, and chose to describe patients
separately. Three patients were described in more detail, because
they were followed (almost) from the start of antibiotic treatment.
Strikingly, in two of these patients (patients 1 and 2), who seemed
to respond well to treatment, the IFN-γ production and the
IFN-γ/IL-2 ratio initially increased, but decreased thereafter. It
is tempting to speculate that this initial increase reﬂects an ade-
quate immune response. A similar initial increase of the speciﬁc
IFN-γ response is seen in patients during treatment for tuber-
culosis (Sahiratmadja et al., 2007). The patient that still showed
signs of infection after more than 2 years of antibiotic treatment
(patient 3), hadmarkedly high IL-2 secretion and a low IFN-γ/IL-2
ratio from the start, which ﬂuctuated in the follow-up but did not
decrease. This might suggest bacterial persistence with low anti-
gen concentrations; an assumption that is supported by the notion
that C. burnetii DNA was not detectable in blood, even before start
of antimicrobial therapy. The results of the total group of patients
with unsuccessful treatment show the same pattern: overall lower
IFN-γ/IL-2 ratio from the start of follow-up in this study, with
no C. burnetii DNA detectable in blood. An exception to this
rule is patient 9, who failed on antibiotic treatment by having C.
burnetii DNA detectable in blood after 20 months of antimicro-
bial therapy. The lower IFN-γ/IL-2 ratio we observed in patients
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FIGURE 4 | Follow-up IFN-γ/IL-2 ratio from chronic Q fever patients during the study follow-up period, separately shown for (A) patients with
endocarditis and (B) patients with vascular (prosthesis) infection. t = 0 is start of antibiotic treatment.
with endovascular infections compared to endocarditis patients
suggests that these manifestations of chronic Q fever differ with
respect to antigen concentrations; vascular infections might be a
more low-grade infection than endocarditis.
Our study has some limitations. First of all, we studied a
relatively small number of patients. Longer follow-up with addi-
tional time points after completion of treatment need to be
incorporated into future studies to evaluate success of treatment.
Moreover, the method we used, in vitro measurement of IFN-γ
and IL-2 production, does not clearly differentiate whether these
cytokines are produced by effector T-cells (producing only IFN-γ)
or effector memory T-cells (producing IFN-γ and IL-2) or central
memory T-cells (producing predominantly IL-2). The ratio IFN-
γ/IL-2 merely reﬂects the overall result and might be inﬂuenced
by the total number of circulating T-cells and their viability in
vitro. To increase our insight in the matter, detection of cytokine
production on single-cell level, e.g., by ﬂow cytometry with intra-
cellular cytokine staining (Harari et al., 2005), would be a valuable
addition in future research.
The central position of serology in Q fever diagnostic is undis-
putable, and serology has hitherto been the most widely used
immunological measurement for C. burnetii infection. It con-
tinues to be extensively validated in Q fever research (Frankel
et al., 2011; van der Hoek et al., 2011; Edouard et al., 2013; Her-
remans et al., 2013). Nevertheless, the immunological importance
of measuring antibodies in response to this intracellular bacte-
rial infection is questionable. Speciﬁcally, the use of antibody
titers to monitor the effect of antibiotic treatment on C. burnetii
infection and disease needs further research. The deﬁnition of
serological cure as anti-phase I IgG below 1:800 (or 1:1024 when
a commercial IFA is used) is based on expert opinion (Million
et al., 2010). The deﬁnition of absence of a fourfold decrease in
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antibody titers as a poor prognostic factor, is based on a small-
sized retrospective study of Q fever endocarditis (Million et al.,
2010), and is not yet conﬁrmed by other studies. In the light
of this limited evidence of serology as a biomarker, it would
be valuable to also focus on the more relevant cell-mediated
immune response. Especially when the decision to continue or
stop treatment has to be made in an individual patient, the avail-
ability of other relevant biomarkers may be of help. Our study
shows a promising role for the IFN-γ/IL-2 production proﬁle,
although the large variation in IFN-γ/IL-2 ratio between patients
in this study makes it difﬁcult to formulate general recommen-
dations for the application of these biomarkers at the current
time.
In conclusion, existing clinical, imaging and microbiological
parameters to monitor the response to treatment have several lim-
itations. We propose that the IFN-γ/IL-2 production proﬁle can
be used as an additional immunological biomarker for treatment
monitoring of chronic Q fever.
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